메뉴 건너뛰기




Volumn 16, Issue SUPPL.A, 2014, Pages

Perspectives: Direct and specific inhibition of factor Xa: An emerging therapeutic strategy for atherothrombotic disease

Author keywords

Acute coronary syndrome; Anticoagulants; Coagulation; Factor X; Myocardial infarction; Secondary prevention; Vitamin K inhibitors; Xa inhibitors

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DAREXABAN; OTAMIXABAN; RIVAROXABAN;

EID: 84892760967     PISSN: 1520765X     EISSN: 15542815     Source Type: Journal    
DOI: 10.1093/eurheartj/sut013     Document Type: Article
Times cited : (11)

References (34)
  • 2
    • 81255167006 scopus 로고    scopus 로고
    • The year in non-ST-segment elevation acute coronary syndrome
    • Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2011;58:2342-2354.
    • (2011) J Am Coll Cardiol , vol.58 , pp. 2342-2354
    • Giugliano, R.P.1    Braunwald, E.2
  • 4
    • 0033552883 scopus 로고    scopus 로고
    • Atherosclerosis-an inflammatory disease
    • Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340:115-126.
    • (1999) N Engl J Med , vol.340 , pp. 115-126
    • Ross, R.1
  • 5
    • 0034648757 scopus 로고    scopus 로고
    • Thrombin signalling and protease-activated receptors
    • Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-264.
    • (2000) Nature , vol.407 , pp. 258-264
    • Coughlin, S.R.1
  • 6
    • 80055098005 scopus 로고    scopus 로고
    • Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?
    • Skeppholm M, Kallner A, Malmqvist K, Blomback M, Wallen H. Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res 2011;128:483-489.
    • (2011) Thromb Res , vol.128 , pp. 483-489
    • Skeppholm, M.1    Kallner, A.2    Malmqvist, K.3    Blomback, M.4    Wallen, H.5
  • 8
    • 23644443663 scopus 로고    scopus 로고
    • Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-analysis with estimates of risk and benefit
    • Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005;143:241-250.
    • (2005) Ann Intern Med , vol.143 , pp. 241-250
    • Rothberg, M.B.1    Celestin, C.2    Fiore, L.D.3    Lawler, E.4    Cook, J.R.5
  • 11
    • 34249025394 scopus 로고    scopus 로고
    • Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: The SEPIA-PCI trial
    • Cohen M, Bhatt DL, Alexander JH, Montalescot G, Bode C, Henry T, Tamby JF, Saaiman J, Simek S, De Swart J. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation 2007;115:2642-2651.
    • (2007) Circulation , vol.115 , pp. 2642-2651
    • Cohen, M.1    Bhatt, D.L.2    Alexander, J.H.3    Montalescot, G.4    Bode, C.5    Henry, T.6    Tamby, J.F.7    Saaiman, J.8    Simek, S.9    De Swart, J.10
  • 12
    • 69949096467 scopus 로고    scopus 로고
    • Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): A randomised, double-blind, activecontrolled, phase 2 trial
    • Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, activecontrolled, phase 2 trial. Lancet 2009;374:787-795.
    • (2009) Lancet , vol.374 , pp. 787-795
    • Sabatine, M.S.1    Antman, E.M.2    Widimsky, P.3    Ebrahim, I.O.4    Kiss, R.G.5    Saaiman, A.6    Polasek, R.7    Contant, C.F.8    McCabe, C.H.9    Braunwald, E.10
  • 14
    • 84862276529 scopus 로고    scopus 로고
    • Novel oral anticoagulants: Focus on the direct factor Xa inhibitor darexaban
    • Apostolakis S, Lip GY. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban. Expert Opin Investig Drugs. 2012;21: 1057-1064.
    • (2012) Expert Opin Investig Drugs , vol.21 , pp. 1057-1064
    • Apostolakis, S.1    Lip, G.Y.2
  • 16
    • 80054733922 scopus 로고    scopus 로고
    • RUBY-1: A randomized, double-blind, placebocontrolled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
    • Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm RW, Granger CB. RUBY-1: a randomized, double-blind, placebocontrolled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011;32:2541-2554.
    • (2011) Eur Heart J , vol.32 , pp. 2541-2554
    • Steg, P.G.1    Mehta, S.R.2    Jukema, J.W.3    Lip, G.Y.4    Gibson, C.M.5    Kovar, F.6    Kala, P.7    Garcia-Hernandez, A.8    Renfurm, R.W.9    Granger, C.B.10
  • 17
    • 84869114866 scopus 로고    scopus 로고
    • Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation
    • Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol 2012;11:1066-1081.
    • (2012) Lancet Neurol , vol.11 , pp. 1066-1081
    • Alberts, M.J.1    Eikelboom, J.W.2    Hankey, G.J.3
  • 25
    • 84876963408 scopus 로고    scopus 로고
    • Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: Results from the ATLAS ACS-2-TIMI-51 trial (anti-xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction-51)
    • Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, Parkhomenko A, Tendera M, Widimsky P, Gibson CM. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction-51). J Am Coll Cardiol 2013;61:1853-1859.
    • (2013) J Am Coll Cardiol , vol.61 , pp. 1853-1859
    • Mega, J.L.1    Braunwald, E.2    Murphy, S.A.3    Plotnikov, A.N.4    Burton, P.5    Kiss, R.G.6    Parkhomenko, A.7    Tendera, M.8    Widimsky, P.9    Gibson, C.M.10
  • 27
    • 84882796805 scopus 로고    scopus 로고
    • The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome ACS 2-Thrombolysis in Myocardial Infarction 51)
    • Krantz MJ, Kaul S. The ATLAS ACS 2-TIMI 51 Trial and the Burden of Missing Data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome ACS 2-Thrombolysis in Myocardial Infarction 51). J Am Coll Cardiol 2013;62:777-781.
    • (2013) J am coll cardiol , vol.62 , pp. 777-781
    • Krantz, M.J.1    Kaul, S.2
  • 28
    • 84869131278 scopus 로고    scopus 로고
    • Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: Systematic review and meta-analysis of randomized controlled trials
    • Komocsi A, Vorobcsuk A, Kehl D, Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:1537-1545.
    • (2012) Arch Intern Med , vol.172 , pp. 1537-1545
    • Komocsi, A.1    Vorobcsuk, A.2    Kehl, D.3    Aradi, D.4
  • 29
    • 84878830133 scopus 로고    scopus 로고
    • New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: A systematic review and meta-analysis
    • Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, Sundstrom J. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 2013;34:1670-1680.
    • (2013) Eur Heart J , vol.34 , pp. 1670-1680
    • Oldgren, J.1    Wallentin, L.2    Alexander, J.H.3    James, S.4    Jonelid, B.5    Steg, G.6    Sundstrom, J.7
  • 31
    • 84882258086 scopus 로고    scopus 로고
    • Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: Striking the right balance between efficacy and safety
    • Patrono C, Andreotti F. Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety. Circulation 2013;128:684-686.
    • (2013) Circulation , vol.128 , pp. 684-686
    • Patrono, C.1    Andreotti, F.2
  • 33
    • 84868523625 scopus 로고    scopus 로고
    • 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association
    • Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
    • (2012) Eur Heart J , vol.33 , pp. 2719-2747
    • Camm, A.J.1    Lip, G.Y.2    De Caterina, R.3    Savelieva, I.4    Atar, D.5    Hohnloser, S.H.6    Hindricks, G.7    Kirchhof, P.8
  • 34
    • 84877762403 scopus 로고    scopus 로고
    • Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation
    • Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013;61:2060-2066.
    • (2013) J Am Coll Cardiol , vol.61 , pp. 2060-2066
    • Sarafoff, N.1    Martischnig, A.2    Wealer, J.3    Mayer, K.4    Mehilli, J.5    Sibbing, D.6    Kastrati, A.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.